FDA records linked by MedtechLedger show one 510(k) entry associated with Ceiba Healthcare US, Inc.: K260075 for eClinics, received January 12, 2026, and decided October 7, 2026 as Substantially Equivalent. The filing lists product code MSX, regulation 870.2300, the Cardiovascular advisory committee, a Traditional clearance type, and a Summary statement. The applicant address on the FDA record is 250 Park Ave. 7th Floor Suite 7012, New York, NY 10177, with Afsin Alp as correspondent and Mary Vater of Innolitics, LLC as correspondent contact. [1][2][3]
The K260075 clearance and its scope
K260075 describes eClinics as a Cardiac Monitor (Including Cardiotachometer And Rate Alarm) under 21 CFR 870.2300, Class II, product code MSX. The decision was Substantially Equivalent, the review was Traditional, and the record states the device was not reviewed by a third party. The FDA database entry lists the decision date as October 7, 2026, and the device classification as a network and communication system for physiological monitors. [1][2][3]
The FDA database entry for K260075 records the applicant as Ceiba Healthcare US, Inc. at a New York, NY address, with Afsin Alp as contact. The clearance letter is addressed to Ceiba Healthcare US, Inc. care of Mary Vater, Director of Regulatory Affairs at Innolitics, LLC, in Austin, Texas. These are filing correspondents and addresses, not verified corporate headquarters. [1][2][3]
What the published documentation says eClinics does
The manufacturer’s documentation describes eClinics as a software-only, web-deployed platform that integrates bedside and EHR data, for example through HL7 interfaces and APIs. It describes configurable multi-patient views, secondary notifications, and advisory clinical decision support such as SOFA and qSOFA scores and a Sepsis Status indicator, along with A/V telehealth, role-based access control, and audit trails. The same document frames the software as a diagnostic aid for situations when the source system cannot be observed directly, not as a replacement for bedside monitors. [2]
Ceiba’s published catalogue describes eConnect as an IoMT technology that captures data from medical devices, states integration with 1,000+ devices and continuing, and sends digital data to the eClinics platform and hospital information systems for real-time display. The catalogue also lists functions including patient lists and geolocation, notes, lab results, live waveforms, and vital values. These are manufacturer statements about product features, not independently verified performance. [8]
Positioning in the company’s own materials
Ceiba’s catalogue presents eClinics within a telehealth portfolio that also names CMS Prime and Dr ICU, and describes a full-spectrum integrated telehealth platform for ICU, ED, and NICU settings. The same catalogue states that Ceiba has obtained approvals and certification for installation in hospitals and medical facilities in the United States, Europe, MENA, and other countries, and that it has partnered with medical device manufacturers and EHR/HIS companies. The specific certifications are not identified in the available text. [6][8]
A Ceiba solutions page describes a telehealth technology platform and multi-specialty clinical services centered on access to care and coordination across inpatient and acute hospital-at-home settings, with medical device connectivity and integration. It also refers to using existing carts and hardwired A/V units to communicate with providers, clinicians, and family members. These descriptions come from the manufacturer’s website. [7]
Applicant identity and collection context
The FDA legal applicant on K260075 is Ceiba Healthcare US, Inc. Published materials also use the names Ceiba Health and Ceiba Healthcare Group, and the catalogue states that Ceiba Healthcare Group has developed healthcare technology solutions since 2016. The available records do not establish the corporate relationship among these names, so parent, subsidiary, or brand status remains unverified. [1][2][4][8]
The linked collection contains one 510(k) record, and the decision count for the full collection is one Substantially Equivalent decision; the record sample likewise contains that single entry. These figures describe the filings assembled as of November 20, 2026, and are not measures of total company sales, total portfolio, or safety performance. No recall records appear in the linked sample. [1]

